| 14th week of 2022 patent applcation highlights part 8 |
| Patent application number | Title | Published |
|---|
| 20220105128 | METHODS OF TREATING VIRAL INFECTIONS AFFECTING THE RESPIRATORY TRACT USING TOPICALLY ADMINISTERED LITHIUM AGENTS - This disclosure relates to topical lithium agents including inhalable lithium agents for treating a viral infection characterized by a cytokine storm in the respiratory tract of a subject such as a human. Topical lithium formulations can be used to mitigate such viral infections, including coronavirus infections. | 2022-04-07 |
| 20220105129 | PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading. | 2022-04-07 |
| 20220105130 | PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading. | 2022-04-07 |
| 20220105131 | PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading. | 2022-04-07 |
| 20220105132 | Method for Producing an Exosome Containing Agent for Metastasis Suppression - Disclosed herein is a method for producing an exosome containing therapeutic agent, including: separating tumor cells from a biomaterial sample of a subject; treating the separated tumor cells in a culture media at 37° C. and at 5% CO2 for 24-72 h; separating an exosome composition from the culture media; and dissolving the separated exosome composition in a phosphate buffer to obtain the exosome containing therapeutic agent; characterized in that the culture media comprises either (i) a 1:1 mixture of DMEM/F12 (Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12) and HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 2 mmol/mL or 3.65 mg/10 mL of L-glutamine, 100 units/mL of penicillin, 100 μg/mL of streptomycin, and 10 wt % of fetal bovine serum; or (ii) 79 wt % of RPMI, 20 wt % of fetal bovine serum and 1 wt % of streptomycin. | 2022-04-07 |
| 20220105133 | TUMOR INFILTRATING LYMPHOCYTES AND METHODS OF THERAPY - Genetically modified compositions, such as non-viral vectors and tumor infiltrating lymphocytes, for the treatment of gastrointestinal cancer are disclosed. Disclosed are methods of utilizing a CRISPR system to generate genetically modified compositions. Also disclosed are the methods of making and using the genetically modified compositions for the treatment of gastrointestinal cancer. | 2022-04-07 |
| 20220105134 | MODIFIED CELL AND USE THEREOF IN GENE AND CELL THERAPY - The present disclosure describes compositions and methods for treating cancer. Embodiments relate to a cell modified to express one or more molecules at a level that is higher or lower than the level of the one or more molecules expressed by a cell that has not been modified to express the one or more molecules, wherein the one or more molecules comprise Cavin3, ZBED2, and MYC. | 2022-04-07 |
| 20220105136 | COMPOSITION AND METHODS OF AN ADVANCED THERAPY FOR NEURODEGENERATIVE DISEASES - The present disclosure relates to a hydrogel comprising: hyaluronic acid, and liposomes physically crosslinked to hyaluronic acid, wherein said hydrogel encapsulates a cell type or a plurality of cell types. The hydrogel of the present disclosure shows a positive therapeutic effect in the treatment or therapy of multiple sclerosis. A pharmaceutical composition comprising a therapeutically effective amount of a hydrogel and a pharmaceutically acceptable excipient/carrier are also disclosed. | 2022-04-07 |
| 20220105137 | BONE AUGMENTATION UTILIZING MUSCLE-DERIVED PROGENITOR COMPOSITIONS, AND TREATMENTS THEREOF - The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment non-soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of non-soft tissue (e.g. bone). Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, bone tissues in the treatment of various functional conditions, including osteoporosis, Paget's Disease, osteogenesis imperfecta, bone fracture, osteomalacia, decrease in bone trabecular strength, decrease in bone cortical strength and decrease in bone density with old age. | 2022-04-07 |
| 20220105138 | MICRONIZED PLACENTAL TISSUE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME - Described herein are compositions composed of micronized placental components and pharmaceutical compositions thereof. The compositions have numerous medical applications. Methods for making and using the micronized compositions are also described herein. | 2022-04-07 |
| 20220105139 | COMPOSITION FOR IMPROVING COGNITIVE ABILITY AND PREVENTING OR TREATING DEMENTIA AND ATTENTION DEFICIT HYPERACTIVITY DISORDER, COMPRISING GALLA RHOIS EXTRACT AND FRAXIN AS ACTIVE INGREDIENTS - The present invention relates to a composition for improving cognitive ability, and preventing or treating dementia and a hyperactivity disorder, which includes a | 2022-04-07 |
| 20220105140 | AGENT FOR INDUCING INTERFERON PRODUCTION CONTAINING LACTIC ACID BACTERIA - This invention provides an IFN inducer comprising, as an active ingredient, lactic acid bacteria and capable of inducing IFN production, an immunopotentiating agent or prophylactic agent against virus infection comprising such inducer, and a food or drink product comprising such IFN inducer and having IFN-inducing activity, immunopotentiating activity, or prophylactic activity against virus infection. The agent for inducing IFN production comprises, as active ingredients, lactic acid bacteria that can activate plasmacytoid dendritic cells (pDCs) and promote IFN production, such as | 2022-04-07 |
| 20220105141 | LACTOBACILLUS REUTERI GMNL-263 FOR IMPROVING HYPERTENSION AND ITS COMPOSITIONS THEREOF - Present invention discloses a | 2022-04-07 |
| 20220105142 | COMPOSITIONS AND METHODS FOR INHIBITING THE PROLIFERATION OF PATHOGENIC ESCHERICHIA COLI - A composition for preventing or treating an infection or disease caused by a pathogenic | 2022-04-07 |
| 20220105143 | T CELL REPERTOIRE DYNAMICS AND ONCOLYTIC VIRAL THERAPY - Provided herein are methods of treating cancer in a subject. The methods include administering to the subject one or more doses of an oncolytic virus (e.g., in an initial round of treatment); selecting a subject with a T-cell population exhibiting high peripheral clonality; and administering to the subject with a T-cell population exhibiting high peripheral clonality a one or more subsequent doses of the oncolytic virus (e.g., in a second round of treatment). | 2022-04-07 |
| 20220105145 | GOLD KIWIFRUIT COMPOSITIONS AND METHODS OF PREPARATION AND USE THEREFOR - The present disclosure encompasses compositions prepared from kiwifruit. In particular, the invention encompasses compositions prepared from gold varieties of | 2022-04-07 |
| 20220105146 | Medical Applications of Cannabis and Hemp Extracts - A method of preparing medical composition including hemp or | 2022-04-07 |
| 20220105147 | CROTON LECHLERI COMPOSITIONS FOR USE IN THE TOPICAL TREATMENT OF ACUTE BACTERIAL SKIN OR SKIN STRUCTURE INFECTION - The present disclosure provides for the treatment of acute bacterial skin or skin structure infections via the topical administration of a pharmaceutical composition comprising a therapeutically effective amount of an extract of the | 2022-04-07 |
| 20220105148 | COMPOSITIONS AND METHODS FOR PREVENTING AND REDUCING INFLAMMATION AND TREATING DISORDERS ASSOCIATED WITH INFLAMMATION - The present invention relates to compositions and methods for preventing and reducing inflammation and preventing and treating diseases and disorders associated with inflammation. It has been shown that CRADD plays a pivotal role in maintaining the integrity of endothelial monolayers. The recombinant cell-penetrating CRADD protein (CP-CRADD)-based compositions and methods described herein provide for the development of a novel treatment for inflammatory vascular disorders including cardiovascular, cerebrovascular, respiratory, gastrointestinal, and renal systems. | 2022-04-07 |
| 20220105149 | WS-635 USES THEREOF IN MEDICINE - The present invention relates to a method of treating, preventing, or lessening postoperative cognitive dysfunction (POCD) in a subject in need thereof, the method comprising the step of administering to the subject a therapeutically effective amount of a compound of Formula I or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, | 2022-04-07 |
| 20220105150 | AMPHIPATHIC ALPHA-HELICAL ANTIMICROBIAL PEPTIDES TREAT INFECTIONS BY GRAM-NEGATIVE PATHOGENS - Antimicrobial agents, including antimicrobial peptides (AMPs), and uses thereof. Compositions and methods of using AMPs that demonstrate activity and improved therapeutic indices against microbial pathogens. The AMPs demonstrate the ability to not only maintain or improve antimicrobial activity against bacterial pathogens including Gram-negative microorganisms | 2022-04-07 |
| 20220105151 | ASARM TREATMENT FOR KIDNEY AND MINERALIZATION DISORDERS AND HYPERPHOSPHATEMIA - A method of treating or inhibiting a kidney disorder can include administering a therapeutically effective amount of the ASARM peptide to provide a treatment for the kidney disorder (treat disease) and/or inhibit development of the kidney disorder (prophylactic). The kidney disorder can be selected from the group consisting of chronic kidney disease mineral bone disorder (CKD-MBD), calciphylaxis, nephrogenic systemic fibrosis (NSF), end stage renal disease, and combinations thereof. The therapy can include inhibiting vascular calcification (VC), hard tissue calcification, soft tissue calcification, mineralization, or combinations thereof in the subject with the ASARM peptide. A method of inhibiting mineralization can include administering a therapeutically effective amount of the ASARM peptide to provide a treatment for inhibit mineralization in the subject. A method of treating hyperphosphatemia can include administering a therapeutically effective amount of the ASARM peptide to a subject to provide a treatment for hyperphosphatemia. | 2022-04-07 |
| 20220105152 | Composition for and Method of Treating Hepatic Tissue Injury - Compositions for and methods of treating liver injury are provided. Said compositions comprise MG53 or express MG53. Said compositions can be used for treating chronic or acute injured liver tissue and can be administered systemically, locally, or both. | 2022-04-07 |
| 20220105154 | Hard Tissue Therapeutics - Compounds, pharmaceutical compositions, and a method of treating hard tissue diseases and disorders are disclosed. The compounds may be a peptide and is structured to bind integrin α | 2022-04-07 |
| 20220105155 | PROTECTION AGAINST STRESS-MEDIATED DAMAGE FROM IONIZING RADIATION - The use and screening of modulators of apoptosis is disclosed. The modulators may be, for example, modulator of NF-κB activity. The modulators may be used, for example, in the treatment of NF-κB-mediated diseases, conditions, and injuries. | 2022-04-07 |
| 20220105156 | METHODS OF TREATMENT FOR KIDNEY DISEASE - The present disclosure provides compositions and methods for treatment of a kidney disease with chemokine protein stromal cell-derived factor 1 (SDF-1), such as methods of treating a subject afflicted with or at risk of developing a kidney disease, comprising administering SDF-1 to a kidney of the subject in a treatment-effective amount. | 2022-04-07 |
| 20220105157 | Compositions and Methods for Promoting Angiogenesis in the Eye - Compositions and methods for promoting angiogenesis in the eye with IL-6 family proteins, including leukemia inhibitory factor (LIF) or cardiotrophin-1 (CT-1) are provided. | 2022-04-07 |
| 20220105158 | USE OF COLLAGEN HYDROLYSATE FOR IMPROVING ENDURANCE PERFORMANCE AND FOR STIMULATING LIPID CATABOLISM - The present invention relates to the use of collagen hydrolysate for improving endurance performance by increasing mitochondrial activity. Further, the invention relates to the use of collagen hydrolysate for stimulating lipid catabolism, and in particular for reducing body weight, by increasing mitochondrial activity. | 2022-04-07 |
| 20220105159 | ANTIMICROBIAL PEPTIDE FOR ONYCHOMYCOSIS - The invention relates to an antimicrobial peptide for use in a method of preventing or treating fungal nail infection (onychomycosis). The invention further relates to a composition comprising an antimicrobial peptide and a pharmaceutically acceptable diluent or excipient, for use in a method of preventing or treating onychomycosis. The invention also relates to a method of treating a patient suffering from onychomycosis, the method comprising administering a therapeutically effective amount of an antimicrobial peptide thereof to the cuticle of a nail affected by onychomycosis. Finally, the invention relates to an antimicrobial peptide comprising the sequence RRRRSVQWCA or ACWQVSRRRR or GRRRRSVQWCA or ACWQVSRRRRG, or a functional mutant thereof, for use in a method for the treatment of a patient suffering from onychomycosis, the method comprising or consisting of the step of administering a therapeutically effective amount of the antimicrobial peptide to the cuticle of a nail affected by the onychomycosis, of said patient. | 2022-04-07 |
| 20220105160 | ARGININE DEIMINASE WITH REDUCED CROSS-REACTIVITY TOWARD ADI - PEG 20 ANTIBODIES FOR CANCER TREATMENT - The present invention relates generally to isolated to arginine deiminase (ADI) proteins that have reduced cross-reactivity with anti-ADI-PEG 20 antibodies as compared to ADI-PEG 20, but which can have functional characteristics comparable to or better than ADI-PEG 20, compositions comprising the ADI proteins, and related methods of treating arginine-dependent diseases or related diseases such as cancer. | 2022-04-07 |
| 20220105161 | PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF THE SYMPTOMS OF ADDICTION AND METHOD OF DIAGNOSING SAME - A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the gastrointestinal tract to determine the presence of symptoms of addiction, and the likelihood of relapsing into addiction is disclosed. | 2022-04-07 |
| 20220105162 | T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF - The present disclosure provides T-cell modulatory antigen-presenting polypeptides, including single-chain antigen-presenting polypeptides and multimeric antigen-presenting polypeptides. The present disclosure provides nucleic acids comprising nucleotide sequences encoding T-cell modulatory antigen-presenting polypeptides of the present disclosure, as well as cells genetically modified with the nucleic acids. A T-cell modulatory antigen-presenting polypeptide of the present disclosure is useful for modulating activity of a T cell. Thus, the present disclosure provides methods of modulating activity of a T cell. | 2022-04-07 |
| 20220105163 | PEPTIDE IMMUNOGENS TARGETING INTERLEUKIN 6 (IL-6) AND FORMULATIONS THEREOF FOR IMMUNOTHERAPY OF DISEASES IMPACTED BY IL-6 DYSREGULATION - The present disclosure is directed to individual peptide immunogen constructs targeting portions of the Interleukin-6 (IL-6) protein, compositions containing the constructs, antibodies elicited by the constructs, and methods for making and using the constructs and compositions thereof. The disclosed IL-6 peptide immunogen constructs contain a B cell epitope from IL-6 linked to a heterologous T helper cell (Th) epitope directly or through an optional heterologous spacer. The IL-6 peptide immunogen constructs stimulate the generation of highly specific antibodies directed to the IL-6 receptor (IL-6R) binding site for the prevention and/or treatment of diseases impacted by IL-6 dysregulation. | 2022-04-07 |
| 20220105164 | Method for Restoring Immune Tolerance In Vivo - The present invention provides a method for restoring immune tolerance in vivo. The invention relates to the use of a recombinant gene encoding auto-antigens or parts thereof for restoring immune tolerance to the auto-antigens in vivo, under transcriptional control of polyomaviral early and late promoters. In a preferred embodiment, the invention relates to the use of recombinant polyomaviral gene delivery vector particles, such as simian virus 40 (SV40) viral vector particles encoding one or multiple auto-antigens or parts thereof under transcriptional control of the SV40 early and late promoter, for restoring immune tolerance to the auto-antigens in vivo. The invention also relates to compositions comprising recombinant genes or polyomaviral vectors and uses thereof as treatment for degenerative or dystrophic diseases. | 2022-04-07 |
| 20220105165 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AS TARGETS OR ACTIVE INGREDIENTS FOR USE IN IMMUNOTHERAPY AGAINST AML AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2022-04-07 |
| 20220105166 | ANUCLEATE CELL-DERIVED VACCINES - The present invention provides methods for stimulating an immune response to an antigen comprising administering to an individual, an anucleate cell-derived vesicle comprising an antigen and/or an adjuvant. In some embodiments, the anucleate cell-derived vesicle comprising the antigen and/or adjuvant is generated by passing a cell suspension containing an input anucleate cell through a constriction, wherein the constriction deforms the input anucleate cell thereby causing a perturbation of the cell to form an anucleate cell-derived vesicle such that an antigen and/or an adjuvant enters the anucleate cell-derived vesicle. In some embodiments, the anucleate cell-derived vesicle comprising the antigen and/or adjuvant is delivered to an individual and the antigen is delivered to and processed in an immunogenic environment to treat a disease, prevent a disease, and/or vaccinate an individual against an antigen. | 2022-04-07 |
| 20220105167 | ESCHERICHIA COLI 0157:H7 PROTEINS AND USES THEREOF - The present invention is direct to isolated polypeptides comprising or consisting of: an amino acid sequence selected from the group consisting of SEQ ID NOs: 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47 or 48; or (a) a variant and/or fragment of (a), for example: (i) a variant of (a); (ii) a fragment of (a); or (iii) a variant of a fragment of (a); together with corresponding isolated nucleic acid molecules, vectors, host cells, methods of production, vesicles, binding moieties, pharmaceutical compositions, kits, methods of treatment and medical uses. | 2022-04-07 |
| 20220105168 | GUT BACTERIA DERIVED MICROVESICLES FOR VACCINE DELIVERY - The present invention relates to a vaccine suitable for immunisation against influenza, plague or | 2022-04-07 |
| 20220105169 | PNEUMOCOCCAL CONJUGATE VACCINE FORMULATIONS - The present invention provides polysaccharide-protein conjugate vaccine formulations comprising a buffer, surfactant, sugar, alkali or alkaline salt, aluminum adjuvant, optionally a bulking agent, and optionally a polymer. | 2022-04-07 |
| 20220105170 | AFRICAN SWINE FEVER VACCINE - Peptides predicted to be immunogenic against African swine fever virus (ASFV) and vaccine compositions that include the peptides are disclosed herein. In some embodiments, these compositions comprise or consist of one or more peptides comprising the amino acid sequence set forth in SEQ ID NOs: 2-2273. In other embodiments, the compositions comprise viral vectors or host cells, or combinations thereof, that comprise one or more of the peptides. In other embodiments, the compositions comprise nucleic acid molecules comprising one or more of the peptides. The compositions disclosed can include one or more additional components, such as, but not limited to, a carrier, an adjuvant, an additional therapeutic, or combinations thereof. Containers and kits that comprise the compositions are described. Uses of the compositions can include administration to an animal to induce an immune response in the animal, or to immunize the animal against ASFV. Administration can be accomplished using one or more of various methods as described herein, such as intramuscular or intranasal administration. | 2022-04-07 |
| 20220105171 | MATERIALS AND METHODS FOR RESPIRATORY DISEASE CONTROL IN CANINES - The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention. | 2022-04-07 |
| 20220105172 | HERPES SIMPLEX VIRUS NANOEMULSION VACCINES AND METHODS OF USING THE SAME - The present application relates to the field of human immunology, in particular, a herpes simplex virus (HSV) vaccine. The subunit vaccine composition comprises isolated surface glycoproteins from herpes simplex viruses, fusion proteins or fragments thereof mixed in varied combination with a nanoemulsion, which is a potent immune enhancer. | 2022-04-07 |
| 20220105173 | VACCINATION USING HERPESVIRUS GENOMES IN NUCLEIC ACID FORM - The present invention provides compositions and methods for inducing immune responses in subjects using HV-based vectors that can be grown in single celled organisms and administered in their nucleic acid form. | 2022-04-07 |
| 20220105174 | RECOMBINANT GALLID HERPESVIRUS 3 VACCINES ENCODING HETEROLOGOUS AVIAN PATHOGEN ANTIGENS - The invention relates to a recombinant Gallid herpesvirus 3 vector encoding heterologous avian pathogen antigens comprising one or more heterologous polynucleotide(s) inserted into the intergenic loci UL3/UL4 and/or UL21/UL22. The invention further relates to vaccines comprising said recombinant Gallid herpesvirus 3 vector and optionally a further Marek's disease virus vector and to a use of the vaccine for protecting an avian species against one or more avian pathogens. Further methods for treating an avian species for protection against one or more diseases caused by avian pathogens and a method for producing the recombinant Gallid herpesvirus 3 vector encoding heterologous avian pathogen antigens is provided. | 2022-04-07 |
| 20220105175 | HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF - The present disclosure provides an immunogenic composition comprising: a) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; b) a T-cell epitope polypeptide comprising a T-cell epitope present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide. The present disclosure provides an immunogenic composition comprising: a) a polypeptide that comprises one or more T-cell epitopes present in an HCV protein other than E1 and E2; and b) a pharmaceutically acceptable excipient. | 2022-04-07 |
| 20220105176 | POLYMERSOMES COMPRISING A COVALENTLY BOUND ANTIGEN AS WELL AS METHODS OF MAKING AND USES THEREOF - The present invention relates to polymersomes capable of eliciting an immune response, comprising: an antigen selected from the group consisting of: (a) a polypeptide; (b) a carbohydrate; (c) a polynucleotide; and (d) a combination of (a) and/or (b) and/or (c); wherein the antigen is conjugated to the exterior surface of the polymersome via a covalent bond. The present invention further relates to a method for production of antigens conjugated to a polymersome as well as to polymersomes produced by said method. The present invention further relates to compositions comprising a polymersome of the present invention, isolated antigen presenting cells or hybridoma cells exposed to the polymersome or composition of the present invention. The present invention also relates to vaccines comprising polymersomes of the present invention, methods of eliciting an immune response or methods for treatment, amelioration, prophylaxis or diagnostics of a cancer, autoimmune or infectious disease, comprising providing polymersomes of the present invention. | 2022-04-07 |
| 20220105177 | ENCAPSULATED GLYCOLIPID ANTIGENS FOR TREATMENT OF NEOPLASTIC DISEASES - Compositions and methods for treating cancer are provided. In particular, the compositions comprise an encapsulated CD1d-restricted invariant Natural Killer T (iNKT) cell antigen, such as glycosphingolipid, for example, α-galactosylceramide. Methods of administering the compositions in combination with a therapy that induces the death of neoplastic cells in the subject are provided. | 2022-04-07 |
| 20220105178 | LI VACCINE ADJUVANT - The present invention relates to a vaccine comprising a nucleic acid construct such as a DNA construct especially a nucleic acid construct comprising sequences encoding invariant chain operatively linked to antigenic protein or peptide encoding sequences. The present vaccine stimulates an enhanced immune response. | 2022-04-07 |
| 20220105179 | GLYCOENGINEERING IMMUNOGLOBULIN E - This disclosure relates to glycoengineering, and methods of utilizing glycoengineering for treating various diseases or disorders (e.g., IgE-mediated disorders). The methods include administering to the subject an effective amount of a composition comprising a fusion protein described herein. In some embodiments, the IgE-mediated disorder is an allergic disorder. In some embodiments, the allergic disorder is an anaphylactic allergy. | 2022-04-07 |
| 20220105180 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS - The present invention describes combination treatment comprising a PD-1 axis binding antagonist and a MEK inhibitor and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer. | 2022-04-07 |
| 20220105181 | METHODS FOR IDENTIFYING BETA-GLUCAN BINDING TO IMMUNE CELLS - This disclosure describes, in one aspect, a method for identifying β-glucan binding to immune cells of a subject. Generally, the method includes obtaining a blood sample from the subject, the blood sample comprising immune cells, adding soluble β-glucan to at least a portion of the blood sample and incubating the mixture under conditions allowing the soluble β-glucan to bind to the immune cells, and detecting soluble β-glucan hound to the immune cells. In another aspect, this disclosure describes a method that generally includes identifying the subject as a low binder of β-glucan, and co-administering to the subject a soluble β-glucan and an antibody preparation capable of converting the subject from a low binder to a high binder. | 2022-04-07 |
| 20220105182 | RADIOTHERAPY IMPROVEMENTS - The invention relates to a method for inducing an abscopal response to radiotherapy in an individual. | 2022-04-07 |
| 20220105183 | MICRO-NANO STRUCTURE FORMED BY SELF-ASSEMBLING ORGANIC SMALL MOLECULE COMPOUND AND USE THEREOF - A micro-nano structure formed by self-assembling a compound represented by formula (I), an isomer thereof, a pharmaceutically acceptable salt, a hydrate or a solvate in an aqueous solution, a preparation method for the micro-nano structure, and use thereof are described. The micro-nano structure has the advantages of having high photothermal conversion efficiency, good photothermal stability, good photothermal effect and photodynamic effect, being easily degraded, and having high safety, and can be passively targeted to tumor sites, having a broad prospect in the diagnosis and treatment of cancers and skin diseases. | 2022-04-07 |
| 20220105184 | COMPOSITIONS, COMBINATIONS AND RELATED METHODS FOR PHOTOIMMUNOTHERAPY - Provided herein are conjugates, compositions and methods for use in photoimmunotherapy, such as photoimmunotherapy induced by activation of a phthalocyanine dye conjugated to a targeting molecule that binds a protein on cell, for example, an IR700-antibody conjugate. In some embodiments, the phthalocyanine-dye conjugate can be activated by irradiation with near-infrared light. Features of the conjugates, compositions and methods, including the dose of the conjugate, provide various advantages, such as lower toxicity and/or improved efficacy. In some embodiments, also provided is a dual label phthalocyanine-dye conjugate in which the targeting molecule is conjugated to an additional fluorescent dye, which can be used for photoimmunotherapy while, for example, also exhibiting improved performance for imaging or detection. Also provided are therapeutic methods using the conjugates and compositions for treatment of diseases and conditions, including tumors or cancers. | 2022-04-07 |
| 20220105185 | RAS INHIBITORS - The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers. | 2022-04-07 |
| 20220105186 | Compositions Containing Nucleosides and Manganese and Their Uses - This invention encompasses methods of preserving protein function by contacting a protein with a composition comprising one or more purine or pyrimidine nucleosides (such as e.g., adenosine or uridine) and an antioxidant (such as e.g., manganese). In addition, the invention encompasses methods of treating and/or preventing a side effect of radiation exposure and methods of preventing a side effect of radiotherapy comprising administration of a pharmaceutically effective amount of a composition comprising one or more purine or pyrimidine nucleosides (such as e.g., adenosine or uridine) and an antioxidant (such as e.g., manganese) to a subject in need thereof. The compositions may comprise | 2022-04-07 |
| 20220105187 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS - The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid. | 2022-04-07 |
| 20220105188 | TARGET PROTEIN EED DEGRADATION-INDUCING DEGRADUCER, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATED TO EED, EZH2, OR PRC2, COMPRISING SAME AS ACTIVE INGREDIENT - The present invention relates to a target protein degradation-inducing Degraducer, a preparation method thereof, and a pharmaceutical composition for preventing or treating diseases related to EED, EZH2, or PRC2 comprising same as an active ingredient. A novel compound represented by formula 1, according to the present invention is a Degraducer compound that induces degradation of a target protein, i.e., EED or PRC2, utilizing cereblon E3 ubiquitin ligase, VHL E3 ubiquitin ligase, MDM2 E3 ubiquitin ligase, and cIAP E3 ubiquitin ligase, wherein the compound has an aspect of remarkably achieving target protein degradation-inducing activity through a ubiquitin proteasome system (UPS), and therefore there is a useful effect in that it is possible to provide a pharmaceutical composition for preventing or treating diseases or conditions related to a target protein, and a functional health food composition for preventing or improving same, comprising said compound as an active ingredient. | 2022-04-07 |
| 20220105189 | POLYETHYLENE GLYCOL CONJUGATED DRUG AND ITS PREPARATION METHOD AND USE - The disclosure relates to the technical field of medicine and in particular to a polyethylene glycol conjugated drug of formula I or a pharmaceutically acceptable salt thereof. The disclosure further relates to a method for preparation and an intermediate of the polyethylene glycol conjugated drug or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the polyethylene glycol conjugated drug or a pharmaceutically acceptable salt thereof, and use of the polyethylene glycol conjugated drug or a pharmaceutically acceptable salt thereof in preparation of a medicament. | 2022-04-07 |
| 20220105190 | METHODS OF USING GLYCOPOLYSIALYLATED THERAPEUTIC PROTEINS - Novel proteins and compounds conjugated with polysialic acid (PSA) are provided herein. Also provided are methods of using these compounds and methods of treatment of various diseases and disorders. The novel compounds provided herein have improved pharmacodynamic and/or pharmacokinetic properties, improved effectiveness, and other desirable properties. | 2022-04-07 |
| 20220105191 | BIOORTHOGONAL COMPOSITIONS - The present disclosure provides bioorthogonal compositions for delivering agents in a subject. The disclosure also provides methods of producing the compositions, as well as methods of using the same. | 2022-04-07 |
| 20220105192 | COMPOSITION, METHOD AND USE THEREOF - A nanoparticle complex for delivery to cells comprising an RNA interference agent and a delivery vehicle comprised of a liposome and peptide. The peptide may be transmembrane, at least part of which is located external to the liposome. The delivery vehicle is used to deliver the RNA interference agent to cells. The RNA interference agent may target the activity of E3 ubiquitin ligase Itch. The complex may be used to treat chemotherapy resistant tumours and/or cancers. Also related compositions, combination, kit, methods and uses thereof. | 2022-04-07 |
| 20220105193 | LINKER PEPTIDE FOR CONSTRUCTING FUSION PROTEIN - A linker peptide for constructing a fusion protein. The linker peptide comprises a flexible peptide and a rigid peptide. The flexible peptide consists of one or more flexible units. The rigid peptide consists of one or more rigid units. The flexible unit comprises two or more amino acid residues selected from Gly, Ser, Ala, and Thr. The rigid unit comprises a human chorionic gonadotropin β-subunit carboxy-terminal peptide (CTP) bearing a plurality of glycosylation sites. The linker peptide can more effectively eliminate mutual steric hindrance of two fusion molecules, decreasing a reduction/loss of polymerization or activity resulting from improper folding of an active protein or a conformational change. On the other hand, the negatively charged, highly sialylated CTP can resist renal clearance, further prolonging a half-life of a fused molecule and enhancing bioavailability of a fused protein. Furthermore, a protective effect of a glycosylated side chain CTP can lower the protease sensitivity of the linker peptide, making a linker region of the fusion protein less degradable. | 2022-04-07 |
| 20220105194 | CONJUGATE COMPRISING LIGAND, SPACER, PEPTIDE LINKER, AND BIOMOLECULE - Provided is a conjugate comprising a ligand, a spacer, and a peptide linker useful for an in-vivo diagnostic drug and internal radiation therapy, using an anti-human MUC1 antibody Fab fragment whose binding activity is not attenuated even by labeling with a metal, a fluorescent dye, or the like. A conjugate comprising 3arm DOTA, a specific spacer, a specific peptide linker, and a biomolecule including an anti-human MUC1 antibody Fab fragment, wherein the binding activity thereof is not attenuated even by labeling with a metal, a fluorescent dye, or the like, can be used as a diagnostic composition and/or a pharmaceutical composition. | 2022-04-07 |
| 20220105195 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER - The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer. | 2022-04-07 |
| 20220105196 | NECTIN-4 ANTIBODY CONJUGATES AND USES THEREOF - The present disclosure provides conjugates of anti-Nectin-4 antibodies or antigen binding fragments thereof to a myeloid cell agonist, compositions comprising the conjugates, and methods of treating cancer with the conjugates. The present disclosure also provides for anti-Nectin-4 antibodies or antigen binding fragments thereof and method for using the antibodies or antigen binding fragments thereof in treating cancer. | 2022-04-07 |
| 20220105197 | ANTIBODY-DRUG CONJUGATE COMPRISING MODIFIED ANTIBODY - The present disclosure relates to an antibody-drug conjugate in which a modified antibody comprising a motif having a specific structure at the end of the antibody is conjugated to a drug via a linker, and a composition comprising the same, and more particularly to a modified antibody-drug conjugate (mADC) comprising a modified antibody that has a significantly increased conjugation yield of drug due to a motif bound to the heavy chain or light chain C-terminus of the antibody, and to a composition comprising the same. | 2022-04-07 |
| 20220105198 | ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPY - The present disclosure relates to, among other things, antibody-drug conjugates comprising a STING agonist cyclic di-nucleotide conjugated to an antibody, preparation methods therefor, and uses therefor. | 2022-04-07 |
| 20220105199 | Sol-Gel Vaults and Methods of Making and Using Thereof - A sol-gel vault which comprises a complex between a vault particle and a sol-gel. The vault particle comprises one or more one or more passenger molecules. At least one of the one or more passenger molecules is an mINT passenger molecule. At least one of the one or more passenger molecules is a protein. At least one of the one or more passenger molecules is an enzyme. The sol-gel is a silica-based sol-gel. | 2022-04-07 |
| 20220105200 | METHODS FOR PREVENTING AND TREATING INFLAMMATION AND INFLAMMATORY DISEASE - Methods of treating, reducing the risk of, preventing, or alleviating a symptom of inflammation or inflammatory disease, including wounds, diabetic ulcer, and inflammatory bowel disease, by administration of gel-based delivery particles, such as zwitterionic copolymer cryogels or chitosan microgels, containing cerium oxide nanoparticles. | 2022-04-07 |
| 20220105201 | LIPID NANOPARTICLE COMPOSITIONS AND METHODS FOR MRNA DELIVERY - Disclosed herein are compositions and methods for modulating the production of a protein in a target cell. The compositions and methods disclosed herein are capable of ameliorating diseases associated with protein or enzyme deficiencies. | 2022-04-07 |
| 20220105202 | UNIVERSAL MULTI-FUNCTIONAL GSH-RESPONSIVE SILICA NANOPARTICLES FOR DELIVERY OF BIOMOLECULES INTO CELLS - The present technology provides a nanoparticle comprising: the polysiloxanes comprise silyloxy subunits having the structure (I) as shown herein, wherein R | 2022-04-07 |
| 20220105203 | CAPPED AND UNCAPPED RNA MOLECULES AND BLOCK COPOLYMERS FOR INTRACELLULAR DELIVERY OF RNA - The present invention relates to the use of at least one tetrafunctional non-ionic amphiphilic block copolymer as a vehicle for capped or uncapped mRNA for intracellular delivery for gene therapy. | 2022-04-07 |
| 20220105204 | Compositions and Methods for the Treatment of Genetic Diseases - This disclosure provides isolated nucleic acid molecules comprising nucleic acid sequences encoding microbial polypeptides that are codon optimized for expression in mammalian cells, vectors comprising an immunotolerant dual promoter system, and methods using these polynucleotides and polypeptides to treat glycogen storage diseases and other inherited diseases. | 2022-04-07 |
| 20220105205 | PSMA-TARGETED NIR DYES AND THEIR USES - The present disclosure relates to prostate specific membrane antigen (PSMA) targeted compounds conjugated to near-infra red (NIR) dyes and methods for their therapeutic and diagnostic use. More specifically, this disclosure provides compounds and methods for diagnosing and treating diseases associated with cells and/or vasculature expressing prostate specific membrane antigen (PSMA), such as prostate cancer and related diseases. The disclosure further describes methods and compositions for making and using the compounds, methods incorporating the compounds, and kits incorporating the compounds. | 2022-04-07 |
| 20220105206 | SENSITIVITY ADVANCES IN ULTRASOUND SWITCHABLE FLUORESCENCE SYSTEMS AND TECHNIQUES - In one aspect, ultrasound-switchable fluorescence (USF) imaging systems are described herein. In some embodiments, such a system comprises an ultrasound source, a fluorophore excitation source, a contrast agent comprising a fluorophore, and an image recording device. The contrast agent, in some cases, comprises a fluorophore associated with a liposome carrier, wherein the contrast agent has a size of up to 1 μm. Further, in some implementations of a system described herein, the image recording device is controlled by a software trigger mode. | 2022-04-07 |
| 20220105207 | Macrocyclic Agents for Targeted Dual-Modality PET and MRI Imaging of Cancer - Dual-modality contrast agents are disclosed herein, having the general formula: | 2022-04-07 |
| 20220105208 | FIBROBLAST ACTIVATION PROTEIN (FAP)-TARGETED IMAGING AND THERAPY - The present teachings relate generally to conjugates and methods for imaging a tumor microenvironment in a patient, and to conjugates and methods for imaging cancer-associated fibroblasts (CAFs) in the tumor microenvironment of a patient. The present teachings relate generally to method of making conjugates comprising a fibroblast activation protein (FAP) inhibitor. | 2022-04-07 |
| 20220105209 | DISPLAY DEVICE WITH ULTRAVIOLET GERMICIDAL LAMP - The display device with an ultraviolet (UV) germicidal lamp includes a display device, an UV germicidal lamp, a power electrically connected to the UV germicidal lamp, a control circuit electrically connected to the UV germicidal lamp, and a fixture member detachably fixing the UV germicidal lamp to a circumferential rim of the display device. The fixture member includes a base, a first clamp piece, and a second clamp piece. The base is joined to the UV germicidal lamp. The first and second clamp pieces are mounted at interval on the base, forming a clamp interval in between. An elastic element is provided between the second clamp piece and the base for forcing the second clamp piece towards the first clamp piece. Therefore, by adjusting the clamp interval, the UV germicidal lamp may be reliably clamped to the display device. | 2022-04-07 |
| 20220105210 | SYSTEM FOR DISINFECTING LARGER SCALE SPACES AND EQUIPMENT - The present disclosure relates generally to systems, devices and methods for disinfection of space and equipment. In particular, the present disclosure relates to systems, devices and methods, such as rolling enclosures, which use light sources, such as ultraviolet (UV) light, and more specifically UV-C light, to disinfect larger scale equipment or spaces. Systems and methods of the present disclosure are particularly useful in medical facilities for treating medical equipment or spaces, where the prevalence of pathogens requires frequent disinfecting. | 2022-04-07 |
| 20220105211 | DISINFECTION DEVICE - A disinfection device may include a body having a mount configured to couple to a surface, a sanitization compartment defining a cavity having at least one open end, at least one light source configured emit sanitizing light into the cavity, and a lid configured to transition between an open position and a closed position, wherein, when the lid is in the closed position, the lid extends over the open end. | 2022-04-07 |
| 20220105212 | SYSTEMS AND METHODS FOR COOLING ULTRAVIOLET (UV) LAMPS - A sanitizing system and method include a sanitizing head including an ultraviolet (UV) lamp, and a cooling manifold configured to deliver air to the UV lamp. The sanitizing system can also include an exhaust sub-system. | 2022-04-07 |
| 20220105213 | DEVICES AND METHODS FOR STERILIZING PROTECTIVE FACIAL MASKS AND MEDICAL GARMENTS USING MICROWAVE ENERGY - The present invention discloses devices and methods for sterilizing protective facial masks and medical garments using microwave energy. Devices include: a fabric sterilization unit for serving as a housing; a water basin disposed inside the sterilization unit, the water basin configured for generating steam in the water basin when exposed to the microwave energy; a nozzle array plate disposed inside the sterilization unit above the water basin, the nozzle array plate configured for increasing the steam pressure by restricting steam escape; an array of steam-jet nozzles with angled upper sections configured for directing a flow of high-pressure, high-temperature steam jets exiting from the nozzles toward at least one fabric material; and material holders for individually positioning and supporting the material such that the steam jets impinge on the material for: sterilizing the material from microbial transmission and/or reproduction; and enabling reusability of the material as suitable Personal Protective Equipment (PPE). | 2022-04-07 |
| 20220105214 | DISINFECTION PASSAGEWAY - The present invention relates to a disinfection passageway with an alerting system. The passageway includes: a first sidewall; a second sidewall; and a top cover extending between the first sidewall and the second sidewall. The passageway also has a storage tank attached to the outer surface of the first sidewall. The storage tank stores sanitizing liquid for dispensing through a plurality of nozzles on the inner surface of at least one sidewall. A temperature sensor is also attached to the passageway, wherein the temperature sensor is adapted for measuring a body temperature of a user. Finally, a hand sanitizer dispenser on the inner surface of at least one side wall adapted for dispensing hand sanitizer. | 2022-04-07 |
| 20220105215 | SYSTEMS AND METHODS FOR DELIVERING CHLORINE DIOXIDE USING A LIQUID CURTAIN - Provided herein are methods and systems for applying chlorine dioxide comprising contacting a target surface with a curtain of a liquid chlorine dioxide treatment solution. The disclosed methods and systems provide improved delivery of chlorine dioxide to target surfaces and have the advantages of providing improved treatment efficacy, improved safety, and reduced chemical usage. The methods and systems can be used for treatment of a variety of surfaces in need of decontamination, including but not limited to food products. | 2022-04-07 |
| 20220105216 | HANDRAIL DISINFECTION SYSTEM FOR VEHICLE WITH HANDRAIL - A handrail disinfection system for vehicle with handrail is mounted on a vehicle having handrail for grasping by an occupant. The handrail disinfection system includes a tank to store disinfectant solution, an exudation part provided on the handrail, an actuator for exuding the disinfectant solution stored in the tank from the exudation part, and a controller for controlling the actuator. At least one processor included in the controller executes upon execution of at least one program, performing a disinfecting process in which the actuator is controlled to exude the disinfectant solution from the exudation part to a surface of the handrail when a predetermined execution condition is satisfied. | 2022-04-07 |
| 20220105217 | ROOM SANITIZER - A room sanitizer has an ozone generator unit having an ozone generator fan. A control unit controls the ozone generator unit. An occupancy sensor connected to the control unit shuts down the ozone generator when the occupancy sensor is activated. The control unit controls an ozone exhaust fan. An ozone destruct module holds ozone destruct catalyst and is connected to the ozone exhaust fan. A remote control is connected to a remote control connector that is electrically connected to the control unit. The remote control further includes a power switch having a power switch warning light, an ozone generator light, and a safe entry light. A remote control cable harness connects the remote control to the control unit. The control unit has an ozone timer relay setting a time for operating the ozone generator, and an ozone destruct timer relay setting a time for operating the ozone exhaust fan. | 2022-04-07 |
| 20220105218 | METHODS AND SYSTEMS FOR REDUCING A PATHOGEN POPULATION - Aspects of the invention include methods for reducing a pathogen population. Methods according to certain embodiments, a source of the pathogen is contacted with a plurality of microdroplets having one or more reactive oxygen species. In certain embodiments, methods include producing the microdroplets by outputting an aqueous composition from an orifice of a flow channel to produce a plurality of microdroplets having one or more reactive oxygen species. In certain embodiments, methods include producing microdroplets through the condensation of water by contacting solid carbon dioxide with an aqueous composition such as by dropping the aqueous composition on the solid carbon dioxide or submerging the solid carbon dioxide in the aqueous composition to produce a plurality of microdroplets having one or more reactive oxygen species. Compositions of a plurality of microdroplets having one or more reactive oxygen species are also provided. Systems for practicing the subject methods are also described. | 2022-04-07 |
| 20220105219 | Door Handle Sanitizer - A door handle sanitizer includes a housing that is mountable to a door and an access lid pivotally attached to the housing. An interior volume of the housing includes a dispensing mechanism having a connector disposed within the interior volume that is configured to removably receive a sanitizer refill container, and a nozzle configured to dispense a sanitizing material onto the door handle. A power supply is operably connected to a motion sensor, a timer, indicator lights, a dispensing mechanism actuator, and a control circuit. The control circuit includes control switches that allow for customization of the door handle sanitizer's spray frequency. If a timer switch is set to a timer interval, then the control circuit activates the dispenser in an interval corresponding to the selected interval. If a motion sensor switch is set to an on position, then the control circuit activates the dispensing mechanism actuator when the motion sensor detects motion. | 2022-04-07 |
| 20220105220 | APPARATUS, SYSTEM AND METHOD FOR ADAPTIVE EMISSION OF RADIATION IN INTERIOR ENVIRONMENTS - A germicidal disinfection apparatus, system and method. Embodiments of the present disclosure include an adaptive germicidal disinfection apparatus, system and method comprising one or more sensors communicably engaged with a controller being configured to control the operation of at least one UV-C emitter. The sensors may be configured to detect various signals from an interior environment and communicate such signals as inputs to the controller. The controller may be configured to process the inputs according to one or more data processing framework to assess and determine a variety of disease control risk factors and trigger conditions. The controller may be configured to configure one or more modes of operation for the at least one UV-C emitter according to an output of one or more data processing operations. | 2022-04-07 |
| 20220105221 | DISINFECTION DEVICES AND METHODS USING THE SAME - Disinfection devices and methods of using the same are described. In embodiments the disinfection devices include a base, a lid, a sanitizing gas supply, a sanitization chamber with an exhaust port and chamber opening, and a fan. When the lid is closed the fan can operate in a first (low flow, high static pressure) flow condition, during which gas may flow through the device at a first (relatively low) flow rate. When the lid is open the fan can operate in a second (high flow, low static pressure) flow condition, during which the fan may exhaust all or substantially all sanitizing gas in the sanitization chamber through the exhaust port over a short exhaust period. The systems and methods can enable a user to rapidly access an article being sanitized with little or no risk of exposure to the sanitizing gas, even when a disinfection operation is in process. | 2022-04-07 |
| 20220105222 | FAN DRIVEN AIR FRESHENER WITH FRAGRANCE END OF LIFE INDICATION - A volatile substance distribution system includes a base unit and a removable capsule. The distribution system further includes an indicator system configured to indicate a usage condition of the capsule. The indicator system includes a capsule sensor, a timing device, and an output device. The capsule sensor is configured to detect that the capsule is in the engaged position. The timing device is configured to track a cumulative usage time of the capsule according to an amount of time the fan is in the operating condition with the capsule in the engaged position as detected by the capsule sensor. The output device is configured to provide an indication of the usage condition when the cumulative usage time reaches a predetermined threshold time. | 2022-04-07 |
| 20220105223 | AIR FRESHENER DESIGN FOR OPTIMIZED AIR FLOW - A volatile substance distribution system includes a fan having a fan profile. The system includes a housing that defines a fluid passage. The fan is disposed in the fluid passage. The housing defines a receptacle configured to removably receive a capsule containing a volatile substance member. The fluid passage is fluidly connected to the capsule when the receptacle removably receives the capsule. The system further includes a shroud surface that partly defines the fluid passage and that opposes the fan. The shroud surface and the fan profile have a corresponding contour. | 2022-04-07 |
| 20220105224 | OPTIMIZING THE SURFACE AREA AND MATERIAL COMPATIBILITY OF A SUBSTRATE IN A CAPSULE TO DISPENSE VOLATILE SUBSTANCE FROM IMPREGNATED SUBSTRATE - A capsule of a volatile substance distribution system having a base unit configured to drive ambient temperature air through the capsule for distributing a volatile substance therefrom. The capsule includes a capsule housing. The capsule also includes a volatile substance member that is housed within the capsule housing. The volatile substance member includes a substrate and a volatile substance on the substrate. The substrate has a porosity that is within a predetermined range for absorption of the volatile substance and for controlled release of the volatile substance from the substrate when the base unit drives air through the capsule. | 2022-04-07 |
| 20220105225 | Smartphone Case With UV LED Sanitizer - A protective smartphone case with UV LED sanitizer configured for attachment to a smartphone includes a plastic smartphone case body having a base, a top end, and a bottom end with four impact resistant sides which form the perimeter of the said smartphone case body; a back cover plate; a fixed bracket; a power connector; a touch switch module; a phone power socket; and an LED ultraviolet light module. Use of the protective smartphone case with UV LED sanitizer includes the steps of attaching a smartphone to the plastic smartphone case body, pointing the LED ultraviolet light module in the direction of the surface or object to be disinfected, positioning the LED ultraviolet light module at an optimal distance from the surface or object, engaging the touch switch module, irradiating the surface or object for a recommended period of time and disengaging the touch switch module. | 2022-04-07 |
| 20220105226 | MINI UVC AIR STERILIZER - The application discloses an air sterilizer. The air sterilizer includes a housing an ultraviolet light generator, and a reflector. The housing is provided with a first cavity, and the housing is provided with an air inlet and an air outlet, both of which are located at the first cavity. The ultraviolet light generator is also located in the first cavity. In the embodiment of the present application, an ultraviolet light generator is placed in the first cavity of the air sterilizer. The air flows in through the air inlet. When the air flows through the first cavity, it is sterilized by the ultraviolet light generator, and then flows out from the air outlet. The toxic or harmful substances in the air can be inactivated by ultraviolet light sterilization, which improves the sterilization and disinfection ability of the air sterilizer, and solves the problem of poor sterilization and disinfection effects of air sterilizers in the prior art. | 2022-04-07 |
| 20220105227 | DUAL CHAMBER ULTRA-VIOLET LED DEVICE FOR USE WITH FACE MASKS TO DISINFECT END-USER'S INHALED AND EXHALED AIR - A breathing protective device including a breathing hose manifold, a dual-chamber sterilization portion including at least one UVC LED lamp, and an end cap. Further disclosed embodiments include, a divider separating the dual-chamber sterilization portion into an intake chamber and an exhaust chamber, an intake check valve in fluid communication with the intake chamber and an inhale port on the breathing hose manifold, an exhaust check valve in fluid communication with the exhaust chamber and an exhale port on the breathing hose manifold, at least one UVC LED lamp in the intake chamber, and at least one UVC LED lamp in the exhaust chamber. | 2022-04-07 |
| 20220105228 | System and Method for Disinfecting Indoor Environments - A system and method for disinfecting an indoor environment. The system includes a user computer having a user app operably coupled with a controller. The user computer communicates with the controller through a network. A UV-C lamp and motion sensor are operably coupled with the controller. The UV-C lamp is operable in a first mode when the indoor environment is occupied to emit ultraviolet radiation to an upper section of the indoor environment at a first level, and a second mode when the indoor environment is unoccupied to emit ultraviolet radiation to sections of the indoor environment beyond the upper section at a level greater than the first level. The method includes the steps of programming parameters for controlling the UV-C lamp remotely, communicating to and storing the parameters on the controller, and controlling the UV-C lamp for operation in the first and second modes. | 2022-04-07 |
| 20220105229 | CCFL STERILIZING APPARATUS - In one aspect, a sterilizing lamp may include a lamp main body, a photocatalyst coating outside the lamp main body, and a CCFL light tube inside the lamp main body. The photocatalyst can be activated by the CCFL light passing out from the lamp main body. An emission material that generates the CCL rays may be enclosed in an internal space of the CCFL light tube. In one embodiment, the photocatalyst in the present invention is TiO | 2022-04-07 |
| 20220105230 | PACKAGING SOLUTIONS - A packaging system for storing ophthalmic devices such as contact lenses and methods for packaging such ophthalmic devices with solutions is disclosed. The packaging system contains an unused, ophthalmic device in an aqueous packaging solution comprising tris(hydroxymethyl)aminomethane or a salt thereof; wherein the solution has an osmolality of at least about 200 mOsm/kg and a pH in the range of about 6 to about 9. | 2022-04-07 |
